Convergent Therapeutics

Convergent therapeutics is a clinical-stage company headquartered in Cambridge, Massachusetts, developing next-generation targeted cancer therapies to improve patient outcomes. Their technology utilizes radioantibodies to precisely target cancer cells without damaging healthy tissue. Their proprietary radioantibodies are internalized into tumor cells, killing them via irreversible DNA damage. Convergent was co-founded in 2021 by physicians and experts in Oncology, Philip Kantoff and Neil Bander.

Jobs: